CLINICAL TRIAL

HDR brachytherapy monotherapy for Prostate Cancer

Low Risk
Waitlist Available · 18+ · Male · Gatineau, Canada

This study is evaluating whether high dose rate brachytherapy is an effective treatment for prostate cancer.

See full description

About the trial for Prostate Cancer

Eligible Conditions
Prostatic Neoplasms · Prostate Cancer

Treatment Groups

This trial involves 2 different treatments. HDR Brachytherapy Monotherapy is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
HDR brachytherapy monotherapy
RADIATION
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for male patients aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Clinical stage T1c, T2a or T2b
PSA less than 20 ng/ml
Gleason Score 6 or 7
Biopsy proven Adenocarcinoma of the Prostate
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 6 weeks, 2 years and 5 years post treatment
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 weeks, 2 years and 5 years post treatment
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 6 weeks, 2 years and 5 years post treatment.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether HDR brachytherapy monotherapy will improve 1 primary outcome, 1 secondary outcome, and 2 other outcomes in patients with Prostate Cancer. Measurement will happen over the course of 5 years.

Disease-free survival
5 YEARS
Disease free survival as evaluated by absence of biochemical recurrence (Phoenix criteria) and absence of clinically/radiologically diagnosed local, regional or distant recurrence.
5 YEARS
Overall survival
5 YEARS
5 YEARS
Gastro-Intestinal (GI) Toxicity
6 WEEKS, 2 YEARS AND 5 YEARS POST TREATMENT
Toxicity according to Expanded Prostate Index Composite (EPIC) questionnaires.
6 WEEKS, 2 YEARS AND 5 YEARS POST TREATMENT
Genito-urinary (GU) toxicity
6 WEEKS, 2 YEARS AND 5 YEARS POST TREATMENT
Toxicity according to International prostate symptom score (IPSS) and Expanded Prostate Index Composite (EPIC) questionnaires.
6 WEEKS, 2 YEARS AND 5 YEARS POST TREATMENT

Who is running the study

Principal Investigator
M. G.
Marc Gaudet, Radiation Oncologist
CSSS de Gatineau

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get prostate cancer a year in the United States?

About 250,000 men will be diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in the US each year. Prostate cancer is the most common cause of death from cancers of the bladder, rectum, stomach or colon and the third most common cause of death by cancer.

Anonymous Patient Answer

What is prostate cancer?

Prostate cancer commonly forms in or between the ages of 70 and 90. It is diagnosed by checking for a lump in the prostate, having been diagnosed with high blood pressure or by other medical tests. It can cause problems with urination and sexual intercourse.

Anonymous Patient Answer

What are the signs of prostate cancer?

Although the combination of age, family history and sexual dysfunction is widely accepted as being helpful in risk stratification, other factors should also be taken into account, given the heterogeneity of the population, including education-level, ethnicity, marital status and the proportion of men without a previous prostatology procedure. Even when adjusting for many known prognostic factors, the percentage of the percentage of PSA and age-adjusted Gleason score that can be used to predict prostate cancer at the time of diagnosis has been found to be surprisingly low.

Anonymous Patient Answer

Can prostate cancer be cured?

For all cancers of the urinary tract, prostate cancer cannot be cured. This applies to patients of all ages and with a range of staging. In the long term, a high proportion of patients with prostate cancer have no symptoms and no evidence of cancer on physical examination. In such cases most treatment is unnecessary.

Anonymous Patient Answer

What causes prostate cancer?

There isn't a clear pathophysiological cause for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) despite the possibility of environmental and genetic factors in its development. However, androgens, including testosterone and dihydrotestosterone (DHT), and other hormones have a role in the development of prostate cancer. Prostate cancer occurs in many tissues, however is most common in the prostate gland, and most commonly in men who have a family history of the disease.

Anonymous Patient Answer

What are common treatments for prostate cancer?

Some prostate cancers can not be treated. They are best treated under the supervision of a prostate cancer specialist. Treatments to prevent other symptoms include medications that can reduce the risk for high blood pressure, diabetes, and osteoporotic fractures; and exercise.

Anonymous Patient Answer

Is hdr brachytherapy monotherapy safe for people?

HDR brachytherapy performed on a routine basis within a multidisciplinary setting can be performed safely. With the potential advantages of short treatment times, low complication rates, and the ability to tailor the treatment to individual needs, HDR brachytherapy continues to provide treatment options to men, many of whom previously had few options.

Anonymous Patient Answer

Is hdr brachytherapy monotherapy typically used in combination with any other treatments?

Hdr brachytherapy is most often used in combination with other treatments and in the treatment of patients with locally advanced prostate cancer. The present findings are in line with data from recent observational studies. However, more randomized-controlled clinical trials are needed.

Anonymous Patient Answer

Have there been any new discoveries for treating prostate cancer?

A number of newer agents are being researched for treating prostate cancer. In addition, there are currently no FDA cleared drugs for treating prostate cancer.\n

Anonymous Patient Answer

How does hdr brachytherapy monotherapy work?

Hd-IMT and HDR-IMRT are equivalent in terms of brentzing and toxicity in T1-2N0 tumors. HDR-IMRT could be the preferred treatment option considering similar efficacy, minimal brentzing and toxicity, and better radiobiological properties, compared to LDR-IMRT.

Anonymous Patient Answer

Does hdr brachytherapy monotherapy improve quality of life for those with prostate cancer?

HDR brachytherapy significantly improves some, but not all, aspects of HRQOL in those with localized prostate cancer. Results from a recent clinical trial support further investigation into better therapies incorporating minimally invasive brachytherapy, or other effective local treatments, for patients with localized prostate cancer.

Anonymous Patient Answer

Who should consider clinical trials for prostate cancer?

A small selection of patients would be willing to participate in clinical trials if they could help control for the major uncertainties of the outcome of these important and cost-effective treatments. Data from a recent study are potentially more relevant to patient s and their clinicians compared with conventional methods of obtaining and interpreting clinical trial outcome data. A small number of prospective trials are available for the treatment of hormone-responsive prostate cancer. However, the results are generally short-lived and are more likely to be biased by the choice of patients and treatment. The outcome of clinical trials is usually not available earlier than eight weeks after the initial treatment is received; there are few data available on patient satisfaction or satisfaction of the treatment.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.